Department of Paediatric Infectious Diseases, Children's Health Ireland at Crumlin and Temple Street, Dublin, Ireland.
School of Medicine, University College Dublin, Dublin, Ireland.
Hum Vaccin Immunother. 2024 Dec 31;20(1):2341505. doi: 10.1080/21645515.2024.2341505. Epub 2024 May 9.
Respiratory Syncytial Virus poses a significant global public health threat, particularly affecting infants aged less than one year of age. Recently, two forms of passive immunization against infant RSV have been developed and brought to market; nirsevimab a long-acting monoclonal antibody (mAb) and RSV-PreF, a maternal RSV vaccine. The acceptability and uptake of these products will play a pivotal role in determining the success of any national immunization strategy aimed at safeguarding infants from RSV. It is crucial at this time to reflect on the factors that influence parental decisions surrounding immunization to facilitate more informed discussions, enhance healthcare communication, and contribute to the design of effective RSV prevention strategies that resonate with the concerns and aspirations of parents worldwide.
呼吸道合胞病毒对全球公共卫生构成重大威胁，尤其对年龄不足 1 岁的婴儿影响较大。最近，已开发出两种针对婴儿呼吸道合胞病毒的被动免疫制剂并推向市场，即长效单克隆抗体 nirsevimab 和 RSV-PreF（一种母亲呼吸道合胞病毒疫苗）。这些产品的可接受性和使用率将在很大程度上决定任何旨在保护婴儿免受呼吸道合胞病毒侵害的国家免疫策略的成功与否。目前，我们需要反思影响父母免疫决策的因素，以便更有针对性地开展讨论，加强医疗保健沟通，并有助于制定有效的呼吸道合胞病毒预防策略，以满足全球父母的关切和期望。
